Penumbra News

Leerink Partners Sticks to Their Buy Rating for Penumbra (PEN)

TipRanksNov 28 17:29

Penumbra Is Maintained at Buy by BTIG

Dow JonesNov 27 01:23

Penumbra Analyst Ratings

BenzingaNov 27 01:14

BTIG Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $270

Futu NewsNov 26 21:31

Cautious Hold Recommendation Amid Uncertainty Following FDA Clearance of Penumbra's Element Vascular Access System

TipRanksNov 26 17:58

Penumbra's Prospective Growth Amidst Market Dynamics Justifies Hold Rating

TipRanksNov 22 19:27

Penumbra Is Maintained at Overweight by Piper Sandler

Dow JonesNov 21 02:13

Penumbra Price Target Raised to $250.00/Share From $235.00 by Piper Sandler

Dow JonesNov 21 02:13

Penumbra Analyst Ratings

BenzingaNov 21 02:06

Piper Sandler Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $250

Futu NewsNov 20 20:31

Truist Financial Maintains Penumbra(PEN.US) With Buy Rating, Announces Target Price $240

Futu NewsNov 6 10:31

Analysts Conflicted on These Healthcare Names: Penumbra (PEN), Kymera Therapeutics (KYMR) and NovoCure (NVCR)

TipRanksNov 5 20:42

Penumbra (PEN) Receives a Buy From BTIG

TipRanksNov 5 18:30

Penumbra's Strong Q3 2024 Performance and Future Growth Prospects Justify Buy Rating by William Plovanic

TipRanksNov 4 20:49

A Quick Look at Today's Ratings for Penumbra(PEN.US), With a Forecast Between $232 to $248

Futu NewsNov 1 21:19

A Quick Look at Today's Ratings for Penumbra(PEN.US), With a Forecast Between $232 to $248

Futu NewsOct 31 21:20

Penumbra Is Maintained at Outperform by Baird

Dow JonesOct 31 20:03

Baird Maintains Outperform on Penumbra, Raises Price Target to $248

BenzingaOct 31 19:51

Penumbra Analyst Ratings

BenzingaOct 31 19:50

Penumbra Analyst Ratings

BenzingaOct 25 18:00